| Name | IPA-3 |
| Description | IPA-3 is a selective, non-ATP competitive Pak1 inhibitor with an IC50 of 2.5 μM, and it does not inhibit group II PAKs (PAKs 4-6). |
| Cell Research | Human primary schwannoma cells are grown on 96 well plates for 2 days. Cells are left untreated or treated with 5 μM IPA-3, 20 μM IPA-3 or 20 μM PIR-3.5 for 24 hours. The MTS-solution is left on the cells for 3 hours, before the absorbance at 490 nm is measured. The experiments are conducted three times and mean and standard error of the mean is calculated with Excel. |
| Kinase Assay | Pak1 (150 nM final) is pre-incubated with MBP (8.3 μM), indicated proteins, and IPA-3 or DMSO in Kinase buffer for 20 minutes at 4°C. Cdc42-GTPγS (3.2 μM) is then added and the reaction is pre-equilibrated 10 minutes at 30°C. Kinase reactions are started by the addition of ATP (to 30 μM) containing [32P]ATP and are incubated 10 min and analyzed by SDS-PAGE and autoradiography. |
| In vitro | IPA-3 is a non-ATP-competitive, allosteric inhibitor of p21-activated kinase 1 (Pak1), with PIR3.5 serving as its control compound. It effectively blocks Cdc42-stimulated and sphingosine-dependent autophosphorylation of Pak1 on Thr423, without targeting the protein's exposed cysteine residues. The efficacy of IPA-3 is dependent on its disulfide bond; reduction by dithiothreitol (DTT) nullifies its inhibitory action on Pak1. Notably, IPA-3 obstructs Pak1 activation by various activators but does not affect already preactivated Pak1; it also impedes PDGF-induced Pak activation in mouse embryonic fibroblasts. This inhibition is partially achieved through covalent binding to Pak1's regulatory domain, an interaction that is both time- and temperature-sensitive, and prevents Cdc42 engagement. Additionally, IPA-3 demonstrates a direct bond to the Pak1 autoregulatory domain and offers reversible inhibition of PMA-induced membrane ruffling in cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.71 mM), Sonication is recommended.
Ethanol : 7 mg/mL (19.97 mM), Sonication is recommended.
DMSO : 250 mg/mL (713.37 mM), Sonication is recommended.
|
| Keywords | PAK1 | PAK | p21 activated kinases | IPA-3 | Inhibitor | inhibit |
| Inhibitors Related | Fingolimod hydrochloride | ZINC194100678 | P505-15 Acetate | PIR 3.5 | PRT062607 hydrochloride | G-5555 | FRAX1036 | FRAX597 | AZ13705339 | GNE 2861 | 5-Aminosalicylic Acid | AZA197 |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | Featured Novel Bioactive Compound Library | Kinase Inhibitor Library | Post-Translational Modification Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Cytoskeletal Signaling Pathway Compound Library |
United States
